St. Jude Calls Shepard To Tend Flock Following Matricaria Abdication
This article was originally published in The Gray Sheet
Executive Summary
Topside personnel changes at St. Jude Medical are unlikely to have a short-term impact on the company's strategic plan, incoming President and CEO Terry Shepard commented during a March 2 teleconference announcing the management changes at the St. Paul, Minnesota device manufacturer.
You may also be interested in...
Urologix restructuring
Minneapolis-based urology firm lays off 26% of its workforce (28 employees), hires Fred Parks as CEO and chairman of the board upon CEO Michael Selzer's resignation. Parks has served as CEO of Marconi Medical Systems and Philips Medical Systems-Cleveland, and held the COO title at St. Jude Medical (1"The Gray Sheet" March 8, 1999, p. 23). Urologix will take a restructuring charge in the fourth quarter...
Urologix restructuring
Minneapolis-based urology firm lays off 26% of its workforce (28 employees), hires Fred Parks as CEO and chairman of the board upon CEO Michael Selzer's resignation. Parks has served as CEO of Marconi Medical Systems and Philips Medical Systems-Cleveland, and held the COO title at St. Jude Medical (1"The Gray Sheet" March 8, 1999, p. 23). Urologix will take a restructuring charge in the fourth quarter...
St. Jude Looks To Jumpstart Cardiac Surgery Business; CHF Next
St. Jude expects U.S. approval of the Biocor andEpic tissue valves to shore up its declining heart valve business. Launch of the Biocor stented tissue valve is anticipated in the first half of 2004